PL367624A1 - Pharmaceutical formulation for the intramuscular administration of fulvestrant - Google Patents

Pharmaceutical formulation for the intramuscular administration of fulvestrant

Info

Publication number: PL367624A1
Authority: PL; Poland
Prior art keywords: fulvestrant; pharmaceutical formulation; intramuscular administration; intramuscular; administration
Prior art date: 2001-07-07

Application number

PL02367624A

Other languages

English (en)

Polish (pl)

Inventor

Julie Kay Cahill

Paul Richard Gellert

Alan Marshall Irving

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-07

Filing date

2002-07-03

Publication date

2005-03-07

2001-07-07 Priority claimed from GBGB0116619.8A external-priority patent/GB0116619D0/en

2002-07-03 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-03-07 Publication of PL367624A1 publication Critical patent/PL367624A1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

PL02367624A 2001-07-07 2002-07-03 Pharmaceutical formulation for the intramuscular administration of fulvestrant PL367624A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0116619.8A GB0116619D0 (en)	2001-07-07	2001-07-07	Formulation
US31571101P	2001-08-30	2001-08-30

Publications (1)

Publication Number	Publication Date
PL367624A1 true PL367624A1 (en)	2005-03-07

Family

ID=26246290

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02367624A PL367624A1 (en)	2001-07-07	2002-07-03	Pharmaceutical formulation for the intramuscular administration of fulvestrant

Country Status (15)

Country	Link
EP (1)	EP1406662A1 (xx)
JP (1)	JP2004534093A (xx)
CN (1)	CN1553815A (xx)
AR (1)	AR037138A1 (xx)
BR (1)	BR0210898A (xx)
CA (1)	CA2453111A1 (xx)
CO (1)	CO5560585A2 (xx)
HU (1)	HUP0400115A3 (xx)
IL (1)	IL159576A0 (xx)
IS (1)	IS7097A (xx)
MX (1)	MXPA04000028A (xx)
NO (1)	NO20040047L (xx)
PL (1)	PL367624A1 (xx)
RU (1)	RU2004102393A (xx)
WO (1)	WO2003006064A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0000313D0 (en)	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
AU2009351590B2 (en)	2009-07-31	2013-07-18	Xi'an Libang Pharmaceutical Technology Co., Ltd.	Fulvestrant nanosphere/microsphere and preparative method and use thereof
CN102600065B (zh) *	2012-03-31	2014-08-13	莱普德制药有限公司	一种氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) *	2012-03-31	2012-07-25	西安力邦制药有限公司	氟维司群或其衍生物缓释制剂及其制备方法
CN102600073B (zh)	2012-03-31	2014-01-01	莱普德制药有限公司	以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
US9271990B2 (en)	2014-02-14	2016-03-01	Fresenius Kabi Usa, Llc	Fulvestrant formulations
JP6682163B2 (ja) *	2016-04-06	2020-04-15	富士フイルム株式会社	医薬組成物
US11590077B2 (en)	2016-05-06	2023-02-28	Eagle Pharmaceuticals, Inc.	Fulvestrant formulations and methods of their use
IL285928B2 (en) *	2016-05-06	2025-06-01	Eagle Pharmaceuticals Inc	Fulvestrant formulations and methods of their use
JP6611932B2 (ja)	2016-05-31	2019-11-27	富士フイルム株式会社	医薬組成物
KR102670293B1 (ko) *	2017-11-08	2024-05-30	이글 파마슈티컬즈 인코포레이티드	풀베스트란트 제제 및 그의 사용 방법
WO2019113361A1 (en) *	2017-12-07	2019-06-13	Nevakar Inc.	Concentrated fulvestrant compositions
CN111465398A (zh) *	2018-01-31	2020-07-28	富士胶片株式会社	注射用制剂的制造方法
CN111481559B (zh) *	2019-01-25	2021-10-08	江苏恒瑞医药股份有限公司	一种高浓度的氟维司群组合物及其制备方法
EP4074304A4 (en) *	2019-12-11	2024-01-10	Shanghai Bocimed Pharmaceutical Co., Ltd.	PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF
WO2023121232A1 (ko) *	2021-12-20	2023-06-29	주식회사 삼양홀딩스	용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
CN118717660B (zh) *	2024-06-12	2025-02-28	湖州亚瑟制药有限公司	一种注射用氟维司群药物组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8813353D0 (en) *	1988-06-06	1988-07-13	Ici Plc	Therapeutic product
GB9525194D0 (en) *	1995-12-12	1996-02-07	Zeneca Ltd	Pharmaceutical composition
GB0000313D0 (en) *	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
GB0008172D0 (en) *	2000-04-05	2000-05-24	Astrazeneca Ab	Therapy

2002
- 2002-07-03 CN CNA028171888A patent/CN1553815A/zh active Pending
- 2002-07-03 IL IL15957602A patent/IL159576A0/xx unknown
- 2002-07-03 CA CA002453111A patent/CA2453111A1/en not_active Abandoned
- 2002-07-03 EP EP02740940A patent/EP1406662A1/en not_active Withdrawn
- 2002-07-03 HU HU0400115A patent/HUP0400115A3/hu unknown
- 2002-07-03 WO PCT/GB2002/003092 patent/WO2003006064A1/en not_active Ceased
- 2002-07-03 BR BR0210898-4A patent/BR0210898A/pt not_active IP Right Cessation
- 2002-07-03 JP JP2003511869A patent/JP2004534093A/ja active Pending
- 2002-07-03 PL PL02367624A patent/PL367624A1/xx not_active Application Discontinuation
- 2002-07-03 RU RU2004102393/15A patent/RU2004102393A/ru not_active Application Discontinuation
- 2002-07-05 AR ARP020102523A patent/AR037138A1/es not_active Application Discontinuation
2004
- 2004-01-05 IS IS7097A patent/IS7097A/is unknown
- 2004-01-06 NO NO20040047A patent/NO20040047L/no not_active Application Discontinuation
- 2004-01-07 MX MXPA04000028A patent/MXPA04000028A/es unknown
- 2004-01-07 CO CO04000761A patent/CO5560585A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1406662A1 (en)	2004-04-14
BR0210898A (pt)	2004-06-22
RU2004102393A (ru)	2005-03-27
MXPA04000028A (es)	2004-05-21
HUP0400115A2 (hu)	2004-06-28
IL159576A0 (en)	2004-06-01
CN1553815A (zh)	2004-12-08
NO20040047L (no)	2004-02-23
CA2453111A1 (en)	2003-01-23
WO2003006064A1 (en)	2003-01-23
IS7097A (is)	2004-01-05
JP2004534093A (ja)	2004-11-11
HUP0400115A3 (en)	2005-11-28
CO5560585A2 (es)	2005-09-30
AR037138A1 (es)	2004-10-27

Publication	Publication Date	Title
HUP0302876A3 (en)	2005-05-30	Pharmaceutical formulation
HUP0401642A3 (en)	2008-05-28	Use of staurosporine derivatives for the preparation of pharmaceutical compositions
GB0118689D0 (en)	2001-09-19	Pharmaceutical formulation
HUP0204137A3 (en)	2005-03-29	Pharmaceutical composition comprising fulvestrant
GB0319041D0 (en)	2003-09-17	Pharmaceutical Formulations
GB0117618D0 (en)	2001-09-12	Pharmaceutical dosage form
IL159576A0 (en)	2004-06-01	Pharmaceutical formulation for the intramuscular administration of fulvestrant
PL366432A1 (en)	2005-01-24	Pharmaceutical formulation
HUP0400200A3 (en)	2008-03-28	Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
AU2002257582A1 (en)	2002-09-04	Pharmaceutical formulation
EP1406493A4 (en)	2006-06-14	ADMINISTRATION OF MEDIUM BY THE PEPT-2 TRANSPORTER
GB0121715D0 (en)	2001-10-31	Pharmaceutical formulations
GB2380129B (en)	2004-08-11	Pharmaceutical formulations
GB0120701D0 (en)	2001-10-17	Pharmaceutical formulations
GB0103638D0 (en)	2001-03-28	Pharmaceutical formulations
GB0127832D0 (en)	2002-01-09	Method for the preparation of pharmaceutical nanosuspensions
IL161306A0 (en)	2004-09-27	Pharmaceutical formulation comprising (r)-bicalutamide
GB0105560D0 (en)	2001-04-25	Pharmaceutical formulations
HUP0200253A3 (en)	2003-04-28	Pharmaceutical compositions for combination therapy
GB0201607D0 (en)	2002-03-13	Formulation for the administration of medicinal substances
GB0104749D0 (en)	2001-04-18	Pharmaceutical formulation
GB0124455D0 (en)	2001-12-05	Pharmaceutical formulations
GB0317345D0 (en)	2003-08-27	Formulation for the administration of medicinal substances
GB0124712D0 (en)	2001-12-05	Pharmaceutical formulation
HUP0103049A3 (en)	2004-03-29	Use of fluexetine for preparation of pharmaceutical compositions

Legal Events

Date	Code	Title	Description
2009-04-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)